J&J: presents results on anticoagulant

(CercleFinance.com) - Johnson & Johnson presented results at the American College of Cardiology 24 on XARELTO (rivaroxaban).
These results show a reduction in the risk of clinically significant bleeding and adverse clinical events.

A new exploratory analysis demonstrates the consistent results of XARELTO in the treatment of patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention.

XARELTO is one of the most studied oral anticoagulants and has been prescribed to more than 10 million patients in the United States.

Despite advances in cardiovascular care, patients with non-valvular AF continue to be at risk of life-threatening cardiovascular events, particularly older patients who are considered difficult to treat due to multiple factors, including age and co-morbidities, said C. Michael Gibson, M.D., DG of the non-profit Baim Institute and Professor of Medicine at Harvard Medical School.


Copyright (c) 2024 CercleFinance.com. All rights reserved.